ROQ vs. BSFA, GENF, VAL, APTA, IXI, EVG, FAB, BVX, IMM, and PYC
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include BSF Enterprise (BSFA), Genflow Biosciences (GENF), ValiRx (VAL), Aptamer Group (APTA), IXICO (IXI), Evgen Pharma (EVG), Fusion Antibodies (FAB), BiVictriX Therapeutics (BVX), ImmuPharma (IMM), and Physiomics (PYC). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics (LON:ROQ) and BSF Enterprise (LON:BSFA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings, community ranking and institutional ownership.
BSF Enterprise received 3 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users.
In the previous week, Roquefort Therapeutics had 1 more articles in the media than BSF Enterprise. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for BSF Enterprise. Roquefort Therapeutics' average media sentiment score of 0.00 equaled BSF Enterprise'saverage media sentiment score.
Roquefort Therapeutics has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500. Comparatively, BSF Enterprise has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.
1.7% of Roquefort Therapeutics shares are owned by institutional investors. 71.0% of Roquefort Therapeutics shares are owned by insiders. Comparatively, 54.6% of BSF Enterprise shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Roquefort Therapeutics' return on equity of -27.46% beat BSF Enterprise's return on equity.
BSF Enterprise has lower revenue, but higher earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than BSF Enterprise, indicating that it is currently the more affordable of the two stocks.
Summary
Roquefort Therapeutics beats BSF Enterprise on 7 of the 11 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ROQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roquefort Therapeutics Competitors List
Related Companies and Tools
